Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.
Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $144.19 which represents a slight increase of $0.17 or 0.12% from the prior close of $144.02. The stock opened at $144.07 and ...